Guidelines for Abstract Submission

Abstract submission will open 19 February 2024
Submit here

Abstract submission will open 19 February 2024

Submission, Deadline

Abstracts have to be submitted exclusively online.

Deadline for submission is 22 April 2024 [11:59 PM - UTC/GMT +1 hour]

Authors can submit their abstracts for oral presentation, poster presentation or both.

There is no difference in submission of abstracts for oral or poster presentations. Submitted abstracts can only be modified prior to the submission deadline.

The presenting author must be listed first and must be the author that submits the abstract.

Topic, Language

Each contribution must relate to one of the featured conference topics.

Each abstract can only be submitted to one featured conference topic.

Abstracts must be submitted and presented in English.

Size, Content

The abstract is limited to 2,000 characters including spaces.

Abstracts must be structured as follows: Background, Case Study / Methods, Results, Discussion/Conclusion

The title should be written in standard sentence style with lower case letters (except first word, names, human gene names [always upper-case letters & italics], etc.).

The text should be grammatically suitable for publication.

Special characters can be included during submission.

Non-standard abbreviations must be defined in the text.

Drugs must be mentioned by generic names, not trade names.

Abstracts must not be used to promote specific drugs, instruments etc.

Submitted abstracts must provide results and not announcements; stating that “Findings will be discussed…” or similar is not acceptable.

The usage of special formatting should be limited. The correct replication in all media cannot be guaranteed.

Conditions, Requirements

The presenter is responsible for compliance with data protection, copyrights, ethical regulations and laws.

The abstract should be novel. It is acceptable to submit abstracts related to information already reported at another conference or in a journal provided that new information will also be presented. The authors should declare this during submission and make clear the new information that will be presented. Please tick the appropriate box “Previous Presentation Disclosure Note”.

To secure anonymity of the review process, names and locations should not be disclosed in the abstract.

Accepted abstracts will be published in a dedicated on-line supplement of the JIMD (Journal of Inherited Metabolic Disease), but this will not include the abstracts accepted for eposters which will only appear in full in the APP, only the title /authors willbe included in the on line issue . Accepted abstracts will be reviewed for typing errors and will be corrected, if necessary.

Authors’ fees or royalties cannot be claimed.

All listed authors have to consent to the abstract text as well as to their publication in all congress media.

Conflicts of interest through commercial benefits have to be disclosed.

In general, the SSIEM does not accept abstracts from companies. Abstracts must not be used to promote specific drugs, instruments etc. The presenter is responsible for compliance with data protection, copyrights, ethical regulations and laws. In cases where there is collaboration between companies and researchers from non-profit organizations, the work might be suitable for an abstract. Such an abstract will undergo standard selection procedures provided that conflicts of interests are clearly stated in detail. If the abstract is selected for an oral or poster presentation the presentation must have been submitted and has to be given by the collaborating researcher that is not employed by the company.

When submitting an abstract, please note that figures and tables are not permitted. Only text is accepted for submission.

Review, Registration

All submitted abstracts will be reviewed anonymously by several international experts.

Evaluation criteria are: Aim(s) and objective(s), materials and methodology, results and conclusions.

Abstracts that contain formal errors (multi-topic submission, not anonymised) will be rejected.

Abstracts may be selected for one of the following presentation forms:

  • Late Breaking News Session on Friday morning
  • Parallel Free Communications Sessions on Wednesday and Thursday
  • Poster displayed throughout the Conference
  • e-Poster available throughout the Conference

E-mail notifications about acceptance or rejection will be sent to the presenting author subsequent to the reviewing process by 14 June 2024

All selected abstracts irrespective of category will appear on the SSIEM APP. Abstracts selected for Oral and Poster presentation will appear in the on- line Abstract book. For those abstracts selected as e-posters  only the titles and the authors names will be included. Conflict of interest should be included for all Abstracts.

Late Breaking News

Abstracts of exceptional originality and importance, completed after 14 June 2024 may be considered for oral presentation in the Late Breaking News Session if submitted before 22 July 2024 directly by e-mail to These abstracts will not be included in the digital issue of Abstracts.